Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users

被引:147
|
作者
Alho, Hannu
Sinclair, David
Vuori, Erkki
Holopainen, Antti
机构
[1] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki 00251, Finland
[2] Univ Helsinki, Dept Forens Med, SF-00300 Helsinki, Finland
[3] Jarvenpaa Addict Hosp, A Clin Fdn, Helsinki, Finland
[4] Univ Helsinki, Res Unit Subst Abuse Med, SF-00300 Helsinki, Finland
关键词
buprenorphine; naloxone; opioids; intravenous opioid abuse; polysubstance abuse;
D O I
10.1016/j.drugalcdep.2006.09.012
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Buprenorphine (Subutex (R)) is widely abused in Finland. A combination of buprenorphine plus naloxone (Suboxone (R)) has been available since late 2004, permitting a comparison of the abuse of the two products among untreated intravenous (IV) users. A survey was distributed to attendees at a Helsinki needle exchange program over 2-weeks in April, 2005, At least 30% were returned anonymously. Survey variables included: years of prior IV opioid abuse, years of buprenorphine abuse, frequency, dosage, route of administration and reasons for use, concomitant IV abuse of other substances and amount paid on the street for both buprenorphine and buprenorphine + naloxone. Buprenorphine was the most frequently used IV drug for 73% of the respondents. More than 75% said they used IV buprenorphine to self-treat addiction or withdrawal. Most (68%) had tried the buprenorphine + naloxone combination IV, but 80% said they had a "bad" experience. Its street price was less than half that of buprenorphine alone. The buprenorphine + naloxone combination appears to be a feasible tool, along with easier access to addiction treatment, for decreasing IV abuse of buprenorphine. (c) 2006 Published by Elsevier Ireland Ltd.
引用
收藏
页码:75 / 78
页数:4
相关论文
共 50 条
  • [31] T-CELL ACTIVATION AND NALOXONE EFFECTS IN IV DRUG-USERS
    LIN, RY
    VALINKSY, J
    RIEBER, M
    FRANKLIN, M
    RAMLALL, R
    NYGREN, E
    [J]. CLINICAL RESEARCH, 1988, 36 (05): : A798 - A798
  • [32] COMPARATIVE ABUSE LIABILITY OF MEPROBAMATE, BUTABARBITAL AND TRIAZOLAM IN RECREATIONAL DRUG-USERS
    ZAWERTAILO, L
    BUSTO, U
    KAPLAN, HL
    SELLERS, EM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 133 - 133
  • [33] RELATIVE ABUSE LIABILITY OF LORAZEPAM AND DIAZEPAM - AN EVALUATION IN RECREATIONAL DRUG-USERS
    FUNDERBURK, FR
    GRIFFITHS, RR
    MCLEOD, DR
    BIGELOW, GE
    MACKENZIE, A
    LIEBSON, IA
    NEMETHCOSLETT, R
    [J]. DRUG AND ALCOHOL DEPENDENCE, 1988, 22 (03) : 215 - 222
  • [34] Relative abuse liability of γ-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users
    Abanades, Sergio
    Farre, Magi
    Barral, Diego
    Torrens, Marta
    Closas, Neus
    Langohr, Klaus
    Pastor, Antoni
    de la Torre, Rafael
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (06) : 625 - 638
  • [35] Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France
    Vidal-Trecan, G
    Varescon, I
    Nabet, N
    Boissonnas, A
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2003, 69 (02) : 175 - 181
  • [37] Medically assisted recovery from opiate dependence within the context of the UK drug strategy: Methadone and Suboxone (buprenorphine-naloxone) patients compared
    McKeganey, Neil
    Russell, Christopher
    Cockayne, Lucinda
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2013, 44 (01) : 97 - 102
  • [38] Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?
    Teuns, Greet B. A.
    Tessari, Michela
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2024, 148
  • [39] Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
    Weiss, Roger D.
    Griffin, Margaret L.
    Potter, Jennifer Sharpe
    Dodd, Dorian R.
    Dreifuss, Jessica A.
    Connery, Hilary S.
    Carroll, Kathleen M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2014, 140 : 118 - 122
  • [40] Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market
    Randhawa, Privia A.
    Brar, Rupinder
    Nolan, Seonaid
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (03) : E73 - E73